Eleven Biotherapeutics Inc. (EBIO) 13.32 $EBIO
Eleven Biotherapeutics Announces Filing of its Annual Report on Form 10-K
Business Wire - Tue Apr 15, 3:01PM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
Eleven Biotherapeutics Added to Russell Indexes on March 31, 2014
Business Wire - Tue Apr 01, 7:31AM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has been added as a member of the Russell 2000(R) and Russell 3000(R) Indexes after the close of market yesterday, March 31, 2014.
Eleven Biotherapeutics to Present Data on Product Candidates at the ARVO 2014 Annual Meeting
Business Wire - Thu Mar 20, 7:30AM CDT
--Preclinical Data on EBI-029 Leverages Cytokine Biology to Target Back Of Eye Disease with Localized Administration
Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005
Business Wire - Tue Mar 04, 3:30PM CST
--Scientific Advice Received from European Medicines Agency
Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors
Business Wire - Mon Mar 03, 7:30AM CST
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company's board of directors.
Eleven Biotherapeutics to Present at March Healthcare Conferences
Business Wire - Wed Feb 26, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., Eleven's President and CEO, is scheduled to present at the following healthcare conferences during March 2014.
Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease
Business Wire - Tue Feb 18, 7:00AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease). EBI-005, the Company's most advanced product candidate generated using its AMP-Rx platform, is a novel, topically administered Interleukin-1 (IL-1) receptor blocker currently in development for the treatment of dry eye disease and allergic conjunctivitis. EBI-005 was designed to bind and block the IL-1 receptor to prevent transmission of biological signals responsible for many of the signs and symptoms of ocular surface diseases.
Eleven Biotherapeutics Closes Initial Public Offering
Business Wire - Tue Feb 11, 10:08AM CST
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments. Eleven's common stock began trading on the NASDAQ Global Market under the ticker symbol "EBIO" on February 6, 2014.
IPO roundup: 5 companies start trading Thursday
AP - Thu Feb 06, 3:45PM CST
NEW YORK (AP) — Five companies began trading publicly on Thursday as the market for initial public offerings continued to go strong following a busy 2013. Three of the five are pharmaceutical companies.
Eleven Biotherapeutics Prices Initial Public Offering
Business Wire - Thu Feb 06, 6:00AM CST
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Eleven. Eleven's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "EBIO" on February 6, 2014. In addition, Eleven has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to 750,000 additional shares of common stock to cover over-allotments.
Eleven Biotherapeutics Announces Filing of its Annual Report on Form 10-K
Business Wire - Tue Apr 15, 3:01PM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
Eleven Biotherapeutics Added to Russell Indexes on March 31, 2014
Business Wire - Tue Apr 01, 7:31AM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has been added as a member of the Russell 2000(R) and Russell 3000(R) Indexes after the close of market yesterday, March 31, 2014.
Eleven Biotherapeutics to Present Data on Product Candidates at the ARVO 2014 Annual Meeting
Business Wire - Thu Mar 20, 7:30AM CDT
--Preclinical Data on EBI-029 Leverages Cytokine Biology to Target Back Of Eye Disease with Localized Administration
Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005
Business Wire - Tue Mar 04, 3:30PM CST
--Scientific Advice Received from European Medicines Agency
Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors
Business Wire - Mon Mar 03, 7:30AM CST
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company's board of directors.
Eleven Biotherapeutics to Present at March Healthcare Conferences
Business Wire - Wed Feb 26, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., Eleven's President and CEO, is scheduled to present at the following healthcare conferences during March 2014.
Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease
Business Wire - Tue Feb 18, 7:00AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease). EBI-005, the Company's most advanced product candidate generated using its AMP-Rx platform, is a novel, topically administered Interleukin-1 (IL-1) receptor blocker currently in development for the treatment of dry eye disease and allergic conjunctivitis. EBI-005 was designed to bind and block the IL-1 receptor to prevent transmission of biological signals responsible for many of the signs and symptoms of ocular surface diseases.
Eleven Biotherapeutics Closes Initial Public Offering
Business Wire - Tue Feb 11, 10:08AM CST
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments. Eleven's common stock began trading on the NASDAQ Global Market under the ticker symbol "EBIO" on February 6, 2014.
IPO roundup: 5 companies start trading Thursday
AP - Thu Feb 06, 3:45PM CST
NEW YORK (AP) — Five companies began trading publicly on Thursday as the market for initial public offerings continued to go strong following a busy 2013. Three of the five are pharmaceutical companies.
Eleven Biotherapeutics Prices Initial Public Offering
Business Wire - Thu Feb 06, 6:00AM CST
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Eleven. Eleven's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "EBIO" on February 6, 2014. In addition, Eleven has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to 750,000 additional shares of common stock to cover over-allotments.
